Giachelli Cecilia M
Department of Bioengineering, University of Washington, Seattle, Washington 98195, USA.
Kidney Int. 2009 May;75(9):890-7. doi: 10.1038/ki.2008.644. Epub 2009 Jan 14.
Vascular calcification is recognized as a major contributor to cardiovascular disease (CVD) in end stage renal disease (ESRD) patients. Susceptibility to vascular calcification is genetically determined and actively regulated by diverse inducers and inhibitors. One of these inducers, hyperphosphatemia, promotes vascular calcification and is a nontraditional risk factor for CVD mortality in ESRD patients. Vascular smooth muscle cells (SMCs) respond to elevated phosphate levels by undergoing an osteochondrogenic phenotype change and mineralizing their extracellular matrix through a mechanism requiring sodium-dependent phosphate cotransporters. Disease states and cytokines can increase expression of sodium-dependent phosphate cotransporters in SMCs, thereby increasing susceptibility to calcification even at phosphate concentrations that are in the normal range.
血管钙化被认为是终末期肾病(ESRD)患者心血管疾病(CVD)的主要促成因素。血管钙化的易感性由基因决定,并受到多种诱导剂和抑制剂的积极调控。这些诱导剂之一,即高磷血症,会促进血管钙化,并且是ESRD患者CVD死亡率的非传统危险因素。血管平滑肌细胞(SMC)通过经历成骨软骨生成表型变化并通过一种需要钠依赖性磷酸盐共转运蛋白的机制使其细胞外基质矿化,来对升高的磷酸盐水平作出反应。疾病状态和细胞因子可增加SMC中钠依赖性磷酸盐共转运蛋白的表达,从而即使在正常范围内的磷酸盐浓度下也会增加钙化易感性。